Aytu BioPharma (NASDAQ:AYTU) Given New $13.00 Price Target at Ascendiant Capital Markets

Aytu BioPharma (NASDAQ:AYTU) had its price target raised by Ascendiant Capital Markets from $12.50 to $13.00 in a report published on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other brokerages also recently commented on AYTU. Zacks Research upgraded Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research note on Monday, November 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a report on Tuesday, October 14th. Wall Street Zen cut shares of Aytu BioPharma from a “buy” rating to a “hold” rating in a research note on Friday, September 26th. Finally, Maxim Group cut their target price on shares of Aytu BioPharma from $9.00 to $7.00 and set a “buy” rating for the company in a report on Thursday, September 25th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $9.33.

Aytu BioPharma Stock Performance

Shares of NASDAQ AYTU opened at $2.28 on Wednesday. The company has a current ratio of 1.23, a quick ratio of 1.08 and a debt-to-equity ratio of 0.45. The company has a 50 day simple moving average of $2.18 and a two-hundred day simple moving average of $2.20. Aytu BioPharma has a 12 month low of $0.95 and a 12 month high of $2.82. The stock has a market cap of $23.23 million, a price-to-earnings ratio of -0.75 and a beta of 0.28.

Aytu BioPharma (NASDAQ:AYTU) last posted its earnings results on Thursday, November 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). The business had revenue of $13.89 million for the quarter, compared to analyst estimates of $17.92 million. Aytu BioPharma had a negative net margin of 20.52% and a positive return on equity of 17.86%.

Institutional Investors Weigh In On Aytu BioPharma

A number of institutional investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP acquired a new position in Aytu BioPharma during the third quarter worth $58,000. FNY Investment Advisers LLC purchased a new stake in shares of Aytu BioPharma during the second quarter worth about $78,000. Persistent Asset Partners Ltd acquired a new position in shares of Aytu BioPharma during the 3rd quarter worth about $117,000. Two Sigma Investments LP raised its position in shares of Aytu BioPharma by 96.2% during the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock worth $129,000 after purchasing an additional 33,701 shares during the last quarter. Finally, Stonepine Capital Management LLC lifted its stake in Aytu BioPharma by 13.8% in the 1st quarter. Stonepine Capital Management LLC now owns 463,721 shares of the company’s stock valued at $556,000 after buying an additional 56,172 shares in the last quarter. Institutional investors and hedge funds own 33.49% of the company’s stock.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.